This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Esophageal Cancer - Surgery

November 23, 2016
The authors queried the NCDB to compare outcomes for patients undergoing induction chemotherapy vs chemoradiotherapy followed by resection for esophageal cancer.  The vast majority received chemoradiotherapy (87.5%), which was associated with a better pCR rate and a lower positive margin rate than chemotherapy.   30 and 90-day mortality rates were si
November 17, 2016
In an interview filmed at the 2016 STS Annual Meeting in Phoenix, Arizona, Daniela Molena discusses her approach to minimally invasive and robotic esophageal surgery.
October 15, 2016
All patients undergoing surgical therapy for esophageal or gastric cancer in France 2010-2012 were evaluated for postoperative mortality stratified by comorbidity score and assessed by medical center volume (low, medium, high, very high).  Most operations were performed in low volume centers.
October 15, 2016
The authors explored the relationship of nodal region and survival from adenocarcinoma of the esophagus/GEJ in patients undergoing induction therapy and transthoracic resection.
October 15, 2016
In this retrospective review, the authors queried whether a hiatal hernia (HH; >5cm) was associated with adverse outcomes after esophagectomy for cancer.  After adjustment, they found that HH patients had a lower rate of complete resection and  lower median survival.
May 5, 2016
In this multicenter study, baseline QOL was assessed in over 200 patients with stage II or III esophageal cancer who underwent induction therapy and surgery or definitive chemoradiotherapy.  Baseline QOL was related to survival independent of age, stage, histologic type, and treatment.  It is suggested that assessment of baseline QOL is a prognostic
April 12, 2016
Whether adding radiotherapy to induction chemotherapy prior to esophagectomy adds a survival benefit is uncertain.  The authors assessed outcomes of 214 patients with T3N1M0 adenocarcinoma among three institutions who underwent induction therapy followed by esophagectomy.   114 patients had chemotherapy and 100 patients had chemoradiotherapy.  90-day
January 12, 2016
30-day and 90-day mortality rates were compared using information from the National Cancer Data Base 2007-2011.  Among nearly 16,000 esophagectomies, the 30-day mortality rate was 4.2% and the 90-day rate was 8.9%.  90-day mortality was uniquely associated with tumor location, tumor stage, and receipt of neoadjuvant therapy.
December 24, 2015
Whether postoperative adjuvant therapy for node-positive residual disease after induction therapy and resection for esophageal cancer is unknown.  This single institution study identified 101 node positive patients among 764 treated with induction therapy and surgery during 2000-2012.  45 of 101 patients who underwent adjuvant therapy, primarily chem
December 23, 2015
This longitudinal review of single institution experience with GEJ adenocarcinomas identified time-related trends.  The proportion of GEJ tumors compared to all esophageal cancers increased from 22% to 36%.  GERD increased from 7% to 11%.  An increased in GERD was associated with an increased in the prevalance of Seiwert I tumors.  There was  a signi